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Background: Antimicrobial stewardship interventions and programmes aim to ensure effective treat-
ment while minimizing antimicrobial-associated harms including resistance. Practice in this vital area is
undermined by the poor quality of research addressing both what specific antimicrobial use in-
terventions are effective and how antimicrobial use improvement strategies can be implemented into
practice. In 2016 we established a working party to identify the key design features that limit translation
of existing research into practice and then to make recommendations for how future studies in this field
should be optimally designed. The first part of this work has been published as a systematic review. Here
we present the working group's final recommendations.
Methods: An international working group for design of antimicrobial stewardship intervention evalua-
tions was convened in response to the fourth call for leading expert network proposals by the Joint
Programming Initiative on Antimicrobial Resistance (JPIAMR). The group comprised clinical and aca-
demic specialists in antimicrobial stewardship and clinical trial design from six European countries.
Group members completed a structured questionnaire to establish the scope of work and key issues to
develop ahead of a first face-to-face meeting that (a) identified the need for a comprehensive systematic
review of study designs in the literature and (b) prioritized key areas where research design consider-
ations restrict translation of findings into practice. The working group's initial outputs were reviewed byt of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Falmer BN1 9PS, United
elyn).
r Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under
g/licenses/by-nc-nd/4.0/).
V.A. Schweitzer et al. / Clinical Microbiology and Infection 26 (2020) 41e5042independent advisors and additional expertise was sought in specific clinical areas. At a second face-to-
face meeting the working group developed a theoretical framework and specific recommendations to
support optimal study design. These were finalized by the working group co-ordinators and agreed by all
working group members.
Results: We propose a theoretical framework in which consideration of the intervention rationale the
intervention setting, intervention features and the intervention aims inform selection and prioritization
of outcome measures, whether the research sets out to determine superiority or non-inferiority of the
intervention measured by its primary outcome(s), the most appropriate study design (e.g. experimental
or quasi- experimental) and the detailed design features. We make 18 specific recommendation in three
domains: outcomes, objectives and study design.
Conclusions: Researchers, funders and practitioners will be able to draw on our recommendations to
most efficiently evaluate antimicrobial stewardship interventions. V.A. Schweitzer, Clin Microbiol Infect
2020;26:41
© 2019 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Background and context
Antimicrobial resistance is a rapidly growing and major threat
to human health [1]. Overuse of antimicrobials drives resistance
at the individual [2] and population level [3]). The term antimi-
crobial stewardship refers to interventions and programmes that
aim to optimize antimicrobial use, achieving effective treatment
while minimizing antimicrobial-associated harms including
resistance [4].
Despite the large and exponentially increasing number of
studies published since the term antimicrobial stewardship was
coined [5e7], evidence remains remarkably weak both for what
specific antimicrobial use interventions are effective (in terms of
mortality, length of stay, adverse events, resistance rates) and how
antimicrobial use improvement strategies can be implemented to
deliver the desired antimicrobial use in daily clinical practice [8]. A
2016 systematic review of evidence supporting key antimicrobial
use interventions (e.g. prescribing according to guidelines, de-
escalation of therapy, intravenous to oral switching) identified
predominantly low-quality and highly heterogenous supporting
evidence [9]. The evidence around improvement strategies is
similarly weak, dominated by uncontrolled beforeeafter studies
and inadequately performed interrupted time series analyses,
mostly performed within single hospitals [10].
We recently reported a broad systematic review of antimicrobial
stewardship intervention studies which highlighted key frequent
designweaknesses [7]. Studies which aim to assess effectiveness of
antimicrobial use interventions are typically underpowered and fail
to provide evidence on safety or even do not report clinical
outcome data at all. Improvement strategy studies are often
multifaceted with inadequate process evaluation to allow media-
tors of impact to be assessed [11]. Generally, the field of antimi-
crobial stewardship research is dominated by single-centre
observational and quasi-experimental studies which fail to deal
optimally with risks of different forms of bias and that lack external
validity [7,8].
Building on this work we established a working group of in-
vestigators in this field that used a consensus-building iterative
process over 12 months to build a conceptual framework and
develop specific recommendations for the design of stewardship
evaluations, which were then reviewed and amended by an expert
advisory committee. This guidance is the final result of that process
and aims to support investigators when making key design de-
cisions and funders assessing proposals for studies of antimicrobial
stewardship interventions and hopefully enhances the quality and
impact of research in this crucial area.Methods
An international working group for design of antimicrobial
stewardship intervention evaluations was convened in response to
the fourth call for leading expert network proposals by the Joint
Programming Initiative on Antimicrobial Resistance (JPIAMR). The
study sponsor was the UK Medical Research Council. The working
group co-ordinators (M.J.M.B., M.J.L.) and co-applicants (V.A.S.,
A.S.W. andC.H.v.W.)purposivelyselectedanadditional eight leading
clinical and academic specialists in antimicrobial stewardship and
clinical trial design from six European countries (France, Germany,
Italy, TheNetherlands, Spain, Switzerland and the UK) to contribute.
Selection secured input from the diversity of professionals involved
in antimicrobial stewardship practice (infection, internal medicine,
intensive care medicine) and research (trial design, statistics and
qualitative research) disciplines. Consensus was sought through a
nominal group process. Group members completed a structured
questionnaire to establish the scope ofwork, key study designs used
in antimicrobial stewardship, identify the major limitations on
different study designs and key issues to develop ahead of a first
face-to-facemeeting. The groupmet inMarch 2017 and anonymized
responses were used for feedback to the whole group and relevant
literature was presented (V.A.S., C.H.v.W., M.J.L.). This identified the
need for a comprehensive systematic review of study designs in the
literature. In parallel, in moderated small group work, candidate
solutionswere proposed to address the limitations identified, and in
a final round-table moderated discussion the group prioritized four
key areas where research design considerations restrict translation
of findings into practice: features of the intervention under evalu-
ation; appropriate selectionof outcomemeasures; demonstrationof
superiority/non-inferiority of the intervention according to the
outcomemeasures selected; and strategies to minimize bias within
experimental and quasi-experimental study designs. The working
group's initial outputs were reviewed by two independent advisory
experts, both senior, clinically active antimicrobial stewardship ex-
perts in different European countries. Their input prompted
widening the group to bring in additional expertise in the field of
implementation research, primary care and paediatrics. A second
face-to-face meeting the working group used the findings of the
systematic review to develop a theoretical framework through
which researchers can address these four key research design con-
siderations. The group proposed a series of key questions re-
searchers can use to highlight themajor issues they need to address
to arrive at an optimal design for their specific researchproject. Final
agreement of recommendations presented here by all 18 members
of the working group was achieved by email.
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The impact of intervention design
Detailed discussion of how antimicrobial stewardship in-
terventions are designed is beyond the scope of this guidance.
However, the design of the scientific evaluation of an intervention
depends on how that interventionwas designed, and this thenmay
depend on a set of interdependent considerations (Fig. 1A). The
intervention rationale should include its basis in theory and
existing evidence (Table 1 is a glossary of terms used in this guid-
ance.). The existing evidence that informed the research question
should be clearly explained on an efficacy-effectiveness-
implementation spectrum [12], as these considerations will deter-
mine how outcomes are selected and prioritized (Fig. 1B). Detailed
characterization of the intervention setting is required to allow
assessment of external validity and to minimize selection bias.
Stewardship interventions are typically multifaceted and each
intervention feature must be specified precisely. The same holds forFig. 1. (A) Interacting considerations relating to the intervention to be evaluated and the
intervention. Adapted from [12].how the intervention's impact will be determined; this will influ-
ence definition and selection of outcomes, selection of clusters/sites
and feasibility of blinding. The intervention aims will be informed
by the rationale and setting and will also be key to selecting the
primary and secondary outcomes; whether these will determine
effectiveness and safety or how implementation results change
antimicrobial use and what data are required to support translation
of study findings into practice. These considerations will inform
whether the research sets out to determine superiority or non-
inferiority of the intervention measured by its primary out-
come(s) against standard practice and the detectable effect sizes/
non-inferiority margins, the most appropriate study design (e.g.
experimental or quasi- experimental) and the detailed design
features.
Recommendations regarding selection of outcome measures
When assessing the impact of a stewardship intervention, re-
searchers should aim to consider all intended and potential unin-
tended effects [13e15]. Outcome measures can be helpfullyir impact on study design. (B) An evaluation pipeline for antimicrobial stewardship
Table 1
Glossary of terms
Term Explanation
Intervention rationale The theory and evidence behind the stewardship intervention which is to be evaluated encompassing external factors (e.g.
behavioural theory, evidence from previous research) and the clinical setting
Clinical setting The environment in which the intervention is evaluated, both physical (e.g. ICU, emergency room, hospital type, primary care,
long-term care) and practical (e.g. prescribing practice, team structures, staffing, behaviour)
Intervention aim(s) The improvement being sought (e.g. reduction in inappropriate antimicrobial prescribing, reduction in use of specific
antimicrobial classes or reduced Clostridium difficile infection)?
Features of the intervention The different elements which make up a multifaceted intervention (e.g. education, decision support)
Cluster A unit representing a group of smaller components, at which an intervention is delivered (e.g. a hospital ward representing all
the doctors working in it, a group of primary care physicians working in a practice)
Outcomes of interest The outcomes measured to determine effectiveness, safety and costs of the intervention
Experimental design studies Studies which use randomization to allocate the stewardship intervention and control, either to individual patients/
professionals or clusters of patients/professionals
Quasi-experimental design
studies
Studies which don't use randomization to allocate the stewardship intervention but rather use as controls different time
period(s) and/or site (s), either external (controlled before-after studies) or internal (interrupted time series analyses, before-
after studies)
Contamination Unintended exposure of patients in the control phase or cluster to some or all of the intervention
Efficacy study A study which assesses whether an antimicrobial use intervention produces the expected result under ideal and controlled
conditions
Effectiveness study A study which assesses whether an antimicrobial use intervention produces the expected result under ‘real-world’ pragmatic
conditions
Implementation Study A study which assesses the impact of an antimicrobial use improvement strategy in daily practice
Mediator analyses Techniques to investigate mechanisms through which complex interventions achieve an observed effect
Superiority analysis An analysis which sets out to determine if the intervention or strategy being assessed is better than comparator
Non-inferiority analysis An analysis which sets out to determine whether the intervention or strategy being assessed not worse (by a prespecified
amount, the non-inferiority margin) than comparator
Process Indicators Measures of the care that is actually delivered to the patients (e.g., empirical regimen according to guideline)
Structure indicators Measures of the organization of the healthcare system (e.g., the availability of a stewardship team)
Ecological assessment (of
antimicrobial resistance)
Measurement of burden if antimicrobial resistant organism(s) or gene(s) in the environment or aggregated patient samples
V.A. Schweitzer et al. / Clinical Microbiology and Infection 26 (2020) 41e5044grouped into three domains as clinical (typically to assess safety of
an antimicrobial-sparing intervention in terms of patient outcome),
microbiological (resistance) and care related (processes and struc-
tures of care, sometimes referred to as quality or performance
outcomes) [16] (Table 2). Whether the study is primarily assessing
effectiveness, implementation or a combination of both, will
determine how outcomes are selected and prioritized, but, in
general, appropriate outcome measures should be prospectively
defined from each of the three domains. It is essential to recognize
that although individually randomized efficacy trials aim to avoid
selection bias, the inevitably restricted populations that enter such
trials can potentially lead to generalisability bias, making extrapo-
lation to wider populations challenging. While stewardship studies
typically assess interventions made at the cluster level, assessment
of clinical, microbiological and care-related outcomes is often
possible at an individual patient level and should be included
where possible to address this.
Clinical outcomes are missing frommany published stewardship
studies. In fact, most of these studies were not sufficiently powered
to exclude clinically meaningful harm. Concern that this prevents
adoption of antimicrobial reduction strategies into practice has led
some to call for routine use of co-primary clinical outcomes in
stewardship evaluations [17]. The working group felt that clinical
outcome measures should always be prespecified and reported.
Exceptions could be implementation studies of interventions for
which concerns over safety will not be a barrier to adoption of their
findings.
Microbiological outcomes address the impact of the intervention
on antimicrobial resistance and/or rates of Clostridium difficile
infection. A central rationale for antimicrobial stewardship in-
terventions is that reducing antimicrobial exposure should reduce
harm to a patient's microbiome and selection for antibiotic resis-
tance. However, the evidence base remains sparse, andmostly of low
quality, with lack of reliable pre-intervention data a particular limi-
tation [9,18,19]. Incorporating assessment of colonization/infectionby resistant organisms within a stewardship study can be chal-
lenging as event rates are often low and the relationship between
antimicrobial exposure and resistancemay be temporally distant and
complicated by interactions with exposure to resistant pathogens
and infection controlmeasures. Theworking group agreed thatwhile
reductions in antimicrobial resistance should not be the primary
outcome of stewardship studies, measurement of prevalence or
incidence of C. difficile infection and of antimicrobial resistance
should be included in the design where possible, and it should be
clear whether measured resistance is in relation to the infecting
pathogen and type of infection or among colonizing strains.
Care provision outcome measures (sometimes called quality or
performance measures) include process indicators, prescribing
behaviours and antimicrobial use data. These are usually relatively
straightforward to obtain and are important to gather and report
since clinical outcomes can only be interpreted meaningfully if it is
clear that patient management has truly changed. Process in-
dicators may address prescribing quality (e.g. guideline adherence
or documentation practice) and reveal mediators of observed re-
sults. They are particularly important in implementation research
to assess how the intervention under evaluation was actually
delivered across the study (fidelity). This allows distinction be-
tween strategies that do and do not change the behaviours they aim
to change and identification of those elements of an intervention
that are impactful and of barriers for implementation [11]. Gath-
ering appropriate qualitative data (e.g. from service managers, care
providers and patients as appropriate) will allow an intervention's
impact on cultural aspects of antibiotic use to be evaluated. Process
outcomes are needed to assess organizational impact, of both
implementation and long-term sustainability. Sustainability
assessment is particularly important when an intervention has
significant organizational-level impact through diversion of activity
or cost [20]. For detailed consideration of these issues researchers
should consult current guidance on development and evaluation of
complex interventions [21].
Table 2
Outcome measures in antimicrobial stewardship evaluations
Examples Notes
Clinical outcome measures
Clinical cure, clinical failure, time to clinical response, recurrence rate.
Mortality, length of stay, need for escalation of care (e.g. from ward to
high dependency or critical care), (re)admission to hospital, revisits.
Patient-reported outcomes (e.g. quality of life measures).
Typically used to determine the safety of the intervention in terms of
patient treatment outcome.
May include microbiological evidence of clinical outcome (e.g.
microbiological cure or recurrence).
Most are directly relevant to the individual patient.
Important safety outcomes which are relatively easy to gather at
cluster-level, but may only be linked partially to the intervention and
may be a long way down the patient pathway
Adverse drug reactions, drugedrug interactions. Gathering relevant data may require individual consent but could be
from a subset of patients or use anonymized electronic records.
Microbiological (resistance) outcome measures
Colonization by antimicrobial resistant pathogens (e.g. MRSA or multi-
drug resistant (MDR) Enterobacteriaceae)
Valuable as short-term surrogate measures of antimicrobial resistance-
related harm but relevance to individual patients is indirect through risk
of antimicrobial resistant infection in the future or through
transmission.
Ecological assessments may be more feasible than individual patient-
level measurement
Infection by specific organisms (C. difficile, antimicrobial resistant
bacteria)
Outcome directly relevant to the impact of the antimicrobial
intervention on the individual patient but uncommon and may require
long follow-up beyond that needed for clinical outcomes
Care provision (quality or performance) outcome measures
Drug use (e.g. Defined daily doses (DDD) or Days of Therapy (DOT) per
admission or per bed-day.
Appropriateness of treatment (e.g. proportion of prescriptions in
accordance with guidelines).
Measures of intervention (e.g. recommendations given, use of clinical
decision support)
Resource requirements (e.g. staff time, clinical consultations, diagnostic
testing)
Costs measures.
Measurement of antimicrobial use (e.g. volume, range of agents) used to
determine whether the intervention has potential to have an effect on
clinical or microbiological outcomes (if no impact on process, then no
clinical/microbiological impact by definition).
Can be selected to measure appropriateness of antimicrobial selection.
Important for health-economic analyses and assessment of
sustainability.
Important for mediator analyses.
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Within each domain of outcome measure, consideration must
be given to appropriate timing depending on the nature of the
intervention and population (e.g. long- and short-term mortality,
clinical complications during hospitalization or after discharge).
Timing of measurement of microbiological outcomes should be
considered to assess impact on resistance including C. difficile and
timing of process outcome measurements should be considered to
assess long-term sustainability.Establishing superiority or non-inferiority
Where a stewardship study sets out to establish the effectiveness
of an intervention, incorporation of appropriate controls is essential if
the results are to inform practice, irrespective of whether an exper-
imental or non-experimental design is used (see below). Researchers
need to decide whether their primary objective is to determine su-
periority or non-inferiority of the intervention vs control.Interventions aiming to improve treatment outcome
In some situations, a relevant clinical benefit can be hypothe-
sized for an intervention (e.g. an intervention that focuses on
increasing earlier targeted treatment based on test results or pre-
venting under-treatment) and a study assessing the effectiveness of
the intervention would seek superiority of the intervention vs.
control for an appropriate primary clinical outcome.Interventions aiming to reduce antimicrobial exposure
In most situations, stewardship interventions aim to preserve
clinical outcome while reducing unnecessary antimicrobial
exposure (e.g. less inappropriate initiation of antibiotics, choice of
narrower spectrum or shorter duration) and improving quality of
prescribing. As a result there is often some degree of real or
perceived risk of patient-level harm, which may be specific to the
intervention, patient population, setting and disease. Researchers
designing effectiveness evaluations should consider what poten-
tial for patient harm would prevent adoption of the intervention
even if it were effective in reducing antimicrobial exposure. Re-
searchers should select appropriate secondary clinical end-
point(s) to address this concern. Ideally in this situation the
research should seek both superiority for an appropriate process
measure and non-inferiority (i.e. not qualitatively worse than
control) for a co-primary clinical outcome. The key measure to
assess non-inferiority is the non-inferiority margin, being the
smallest outcome difference for which the intervention would be
considered no worse than control. The size of the non-inferiority
margin strongly influences the sample size required to demon-
strate non-inferiority with sufficient power. What margin is
chosen depends on the outcome selected. The margin needs to be
small enough to exclude relevant harm, which would prevent
intervention implementation into practice. Researchers should
justify the non-inferiority margin chosen with regard to severity
and frequency of the outcome in the control group (which may,
for example be affected by case mix [22].
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clinical outcomes usually require large sample sizes. In such trials
an interim analysis of a process outcome could be used to deter-
mine futility; if the intervention does not lead to the pursued
process change continuing that intervention may not be logical, as
non-inferiority will be the inevitable outcome.
Recognizing that achieving adequate power to exclude clinically
relevant non-inferiority will not always be feasible, the group felt
that researchers should at least specify and report point estimates
and confidence intervals for a single prespecified lead clinical
outcome. Bayesian analyses may be helpful to directly estimate the
probability that intervention is more than 2.5%, 5%, 7.5%, etc.,
inferior to control [23]. Researchers should also prespecify the
clinical outcomes they will use to assess the safety of the inter-
vention, and all available clinical outcome data should be reported,
in order to allow future meta-analysis. Unavailability of data should
be explained. Unplanned exploratory analyses of clinical outcomes
should be reported as such.
In studies addressing how interventions with established effi-
cacy should be implemented, the quantitative outcome measures
will be predominantly process measures and comparisons will seek
to determine superiority of the intervention over comparator.
Sample size calculations
Studies evaluating effectiveness of an antimicrobial intervention
need to be powered to demonstrate clinically relevant non-
inferiority. In a superiority trial, detecting a large effect with high
probability is almost always possible at a feasible sample size.
Whereas demonstrating superiority only requires the confidence
interval for the effect estimate to exclude zero, regardless of its
width, determining non-inferiority requires the entire confidence
interval to lie below the non-inferiority margin [24]. As a result,
much larger participant numbers are usually required to demon-
strate non-inferiority within clinically relevant margins which may
be very small and difficult to define for outcomes such as mortality
[25]. This difference lies in that superiority trials tend to be pow-
ered on an expected effect, which is often larger than what would
be deemed a clinically relevant effect, whereas non-inferiority trials
need to be powered on a clinically relevant effect.
One proposed solution to this issue is the Desirability of
Outcome Ranking (DOOR)/Response Adjusted for Days of Antibiotic
Risk (RADAR) approach, which uses investigator-ranked composite
outcomes. This approach is based on the assumption that the same
outcome with less antimicrobial exposure is desirable [26]. Yet,
problems with clinical interpretation and sensitivity to the clinical
outcomes chosen have been reported [27,28]. It remains to be
determined to what extent the RADAR approach can robustly
establish the effectiveness of novel stewardship interventions.
Interrupted time series studies require enough sequential
measures before and after the intervention; the study's power will
depend on the number of data points, their distribution, variability,
the expected strength of the intervention effect and confounding
factors such as seasonality [29], and therefore there are no
straightforward sample size formulae. Researchers should consider
the minimal requirements set out in the Cochrane Effective Practice
and Organisation of Care (EPOC) resources [30].
Study design
Stewardship interventions typically target prescribers or other
healthcare professionals rather than individual patients. As a
consequence, evaluations involving individual patient randomiza-
tion are usually not possible because of contamination. Instead,
intervention allocation must be clustered (e.g. hospital, ward,primary care practice or physician). An important advantage of
allocation at the cluster level is that it is more representative of
real-life clinical practice. It is therefore more suited to studying
both antimicrobial use interventions and antimicrobial improve-
ment strategies rather than efficacy. Whereas in individual patient
trials, randomization can be expected to control for confounding
bias and maximize internal validity, with cluster randomized
controlled trials (cRCTs), researchers need to give careful consid-
eration to how clusters are defined and characterized. Clusters
should be defined at the lowest level (e.g. clinical team, ward,
practice, hospital) where contamination is unlikely as this will
maximize the number of available clusters and hence study power.
However, with the small number of clusters typically available in
stewardship evaluations, randomization cannot be relied on to
avoid imbalance between intervention and control clusters.
Therefore baseline imbalances which may influence the inter-
vention's impact (e.g. antimicrobial use, antimicrobial resistance
rates, infection control standards, antimicrobial stewardship
structures and processes, casemix of patients) should be specified a
priori and data on these should be gathered for inclusion in
multivariate analyses. Baseline imbalance in factors which a strong
association with outcome or that could potentially modify the ef-
fect of the intervention can be addressed through stratified
randomization (e.g. putting clusters into similar pairs and allo-
cating one of each pair randomly to intervention vs. control), or use
of a crossover design (see below). Cluster characterization is also
essential to understand any observed heterogeneity of the inter-
vention's effect between clusters. It optimizes external validity by
allowing others to judge the representativeness for their clinical
practice and to understand the logistical challenges of
implementation.
Experimental study designs
Three main forms of cluster-randomized design may be appro-
priate depending on the intervention (Table 3). As above, parallel
cRCTs, in which each cluster is randomized to either the interven-
tion or control, minimize risk of contamination and maximize in-
dependence of the intervention from cluster-level characteristics.
In some situations, perceptions of the intervention may influence
whether clusters are willing to be randomized to control or inter-
vention arms and hamper participation or introduce bias. Stepped-
wedge cRCTs (swcRCTs) overcome this issue since all clusters receive
the intervention during the trial, and allow estimation of the
intervention effect within each cluster. swcRCTs can be logistically
challenging to deliver since some clusters may have to wait to
introduce the intervention and exposure should be avoided.
Furthermore, the analysis of swcRCT is more complex [31].
Randomization of time of implementation is crucial to ensure in-
dependence of the timing of introduction from cluster-level factors.
Crossover cRCTs offer the potential to estimate intervention effects
in both directionsdi.e. introducing and withdrawing, but may not
be practicable (e.g. it may not be feasible to withdraw an educa-
tional intervention. Alternatively, the washout phase of a crossover
study may be considered an assessment of sustainability for some
forms of intervention. Assessment of carried antimicrobial resis-
tance in crossover designs may need to consider the potential for
resistance selection to persist.
A particular challenge with evaluation of interventions made at
a cluster rather than patient level is intracluster correlation [32].
This must be incorporated into the sample size calculation other-
wise a trial may be underpowered. Intracluster correlation is the
extent to which patients are more similar to each other within a
cluster than they would be if selected at random. The intracluster
correlation coefficient (ICC) of an outcome is a measure of the
relatedness of clustered data by comparing the variance within
Table 3
Design recommendations for experimental evaluations antimicrobial stewardship Interventions
Feature Recommendations
Parallel cRCTs Stepped-wedge cRCTs Crossover cRCTs
Cluster selection Randomized implementation at the lowest level (e.g. prescriber, ward, hospital, primary care practice) at which contamination can be
minimized
Define eligibility criteria and document representativeness of included clusters with respect to system from which they are drawn
(e.g. size, case mix)
Cluster allocation and
randomization, timing of
intervention
Ensure allocation concealment until the intervention is
implemented (as complete blinding to allocation after
randomization is often not feasible)
Conceal timing and order of intervention/crossover as much as
possible
Timing of intervention should be determined externally and at
random, where possible
Cluster balance Pursue good/excellent balance between clusters (e.g.
matching, stratified randomization based on factors likely to
be associated with the outcome under study). No lower
limit above which randomization will ensure balance but
particularly problematic if there are fewer than 20 clusters
per randomized group
Collect data to document balance between clusters
Good/excellent balance between clusters achieved through design
Blinding Consider the objectivity of the selected outcomes and the extent to which patients and assessors of outcomes can be blinded to the
cluster allocation
Outcomes Specify a primary or co-primary process outcome
Specify a co-primary clinical outcome or at minimum one lead clinical outcome, and specify and report secondary clinical outcomes
even if not powered on these
Specify and analyse outcomes in each domaindclinical, microbiological, process (quantity or quality of antimicrobial use)
Within implementation research, process outcomes should be selected with regard to complex intervention methodology [21], e.g.
measures of fidelity, mediators and modifiers of the intended effect and measures of organizational impact
Consider all important harms/unintended effects including ‘squeezing the balloon’ effects in which achieving the intended reduction
in antimicrobial overuse results in an unintended increase in harmful overuse elsewhere [14,15,38]
Define timing of different cluster-level and individual-level outcomes
Power calculation Provide sample size calculations to demonstrate study powerdfor the primary/co-primary outcome(s), and taking intra-cluster
correlation into account
Analysis Adjust for secular trends (particularly for stepped-wedge cRCTs)
Selection of patients for
outcome evaluation
Ensure robust consistent inclusion of patients in control and intervention clusters/phases
Report denominators from whom included patients were selected wherever possible
Follow-up of patients Timing of patient follow-up to assess patient-level outcomes should consider relevant time scales for both effectiveness and harms
Follow-up of clusters Consider duration of follow-up both for immediate effect of the intervention and sustainability Only possible with short-term
interventions with rapid loss of
effect post withdrawal
Reporting Report according to CONSORT criteria for cluster RCTs, stepped-wedge cRCTs, and other CONSORT guidelines as appropriate (e.g.
pragmatic trials, non-inferiority trials). Consider using the TiDier checklist to clearly describe any behavioural intervention [39]
CRCT, cluster randomized controlled trial.
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ICC means that observations within clusters are much more similar
to each other than to observations in other clusters, while an ICC of
zero means that observations within one cluster are equally similar
to each other than to observations in other clusters. In general, if
the ICC is large, research designs with crossover are more efficient,
while if the ICC is low, parallel cluster designs are more efficient
[32].
Quasi-experimental study designs
In situations where randomization is not feasible or ethically not
acceptable (see below), quasi-experimental, beforeeafter studies
have the potential to deliver robust evidence of a causal relation-
ship between an intervention and measured outcomes if they
incorporate appropriate controls and analyses which account for
time trends (Table 4). Where control is provided through compar-
ison with centre(s) where the intervention is not introduced, the
term controlled beforeeafter (CBA) study is used. Where control is
provided by use of pre-intervention observations within centres,
and secular time trends in the outcomes are specifically accounted
for, the term interrupted time series (ITS) study is used. In practice,
ITS reflects a method of analysis, being used for before and after
studies and CBA, rather than a specific study type and can also be
applied to CBA studies. CBA studies which do not control for time
trends are unlikely to provide reliable evidence, regardless of
external control [19]. The working group agreed that design of
quasi-experimental evaluations of stewardship interventions mustalways account for changes in time [33,34]. Such analyses require
sufficient pre-intervention time points to incorporate segmented
regression analysis, and should consider adjustment for autocor-
relation (e.g. using ARIMA models). Such analyses should report
immediate effects on outcome and trends before and after the
implementation, and assess whether trends are non-linear [29,35].
Furthermore, the timing of intervention implementation must be
externally set to avoid the problem of regression to themeanwhich
occurs when sites introduce a stewardship intervention in response
to deterioration in the chosen outcomemeasure. Detailed guidance
on conduct of Interrupted Time Series analyses are available
through EPOC [30] and described in a recent review [36].
Ethical considerations
Antimicrobial stewardship measures which balance immediate
and individual risks against future and societal access to effective
antimicrobials raise challenging ethical issues around intergener-
ational justice, global distributive justice and protection of public
health [37]. A key ethical issue in stewardship research is that, by
gathering evidence for safety through clinical outcome measures,
the possibility of individual harm is acknowledged. Individual pa-
tient consent may not be feasible in studies of interventions which
act on prescribers or structures such as hospitals or clinics. Thismay
set a higher ethical barrier than for individually randomized studies
in which informed consent can be obtained. In this situation the
research design process should involve patients to ensure that
Table 4
Design recommendations for quasi-experimental evaluations antimicrobial stewardship Interventions
Feature Recommendations
Control Even in situations where randomization is not possible (e.g. too few available clusters) allocation to intervention or control group should be
made externally if at all possible, i.e. not depending on known factors or clinician preference
Consider trying to match controls to minimize risk of bias arising from intrinsic differences between control and intervention groups
Timing Timing of intervention should be externally set OR if this is not possible timing must be explained and described
Data Data from automated electronic data recording (e.g. antimicrobial use data, routine electronic patient data) can be used retrospectively for
pre-intervention data providing that collection/entry is consistent over calendar time, otherwise all data should be collected prospectively
Measure, report and analyse any concurrent changes in case-mix, changes in methodology of outcome assessment, and care practices
Analysis Include at least 12 monthly time points before and after the intervention to allow for anticipated secular trends [36,40]
Use segmented regression or ARIMA models to account for secular trends
Include at least 100 observations per time point [40]
Check and, if necessary, correct for autocorrelation
Outcomes See Table 3
Follow-up of patients Timing of patient follow-up to assess patient-level outcomes should consider relevant timescales for both effectiveness and harms
Follow-up of clusters Consider duration of follow up both for immediate effect of the intervention and sustainability
Reporting Report according to relevant recommendations; STROBE-AMS [41] or STROBE [42] and the TiDier checklist [39], SQUIRE to describe in detail
quality improvement component of study [43], TREND statement for nonrandomized evaluations of behavioural and public health
interventions [44]
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lation about these trade-offs are heard, actively considered, and
incorporated into the final design. Additionally, researchers should
be able to justify why the interventions under examination are
reasonable choices of practice which could also be made outside
the study setting. Studies in which the intervention is made at a
cluster level will often still use individual patient data. Any
requirement for individual patient consent to collect data may lead
to loss of representativeness and a biased assessment of the
intervention effect. Because consent is acquired with knowledge of
the intervention, there is an increased risk of selection bias, e.g. if
investigators are more motivated to enrol patients during the
intervention period. Depending on the national regulations, in
some countries study designs can address this issue through use of
de-identified or anonymous data (e.g. through electronic patient
records) of parameters collected routinely in clinical practice
without the need for individual patient consent.Key design decisions
The consensus group considered that researchers planning
antimicrobial stewardship evaluations must make a set of key de-
cisions (Table 5) that will ultimately determine optimal study
design. We have classified these decisions based on whether they
apply to the intervention itself, the evaluation setting, the outcomes of
interest, the research objective and type of study. Detailed explana-
tion of the decisions are presented (please see supplementary
materials).Discussion and conclusions
The theoretical framework and design recommendations we
present have been developed by a diverse international working
group with broad and substantial expertise in antimicrobialTable 5
Key design decisions. A detailed explanation of the rationale and how these address diff
Question
Where does knowledge gap the study aims to address lie on a spectrum between ‘wh
What are the risks of contamination?
Is it possible to remove the intervention after it has been implemented?
Is the intervention impact threatened by sustainability?
What forms of bias threaten the validity of the study?
What features of the evaluation setting will impact on external validity?
Is it possible to blindly assess the outcome?stewardship research and practice. They address aspects of study
design which are crucial to translation of research into practice
and will, we believe, increase the impact of future research in this
field. By drawing on wide expertise and building on our
comprehensive systematic review we consider our recommen-
dations relevant across diverse settings of care. Our work has
some notable limitations. Although we gave careful consideration
to the breadth of expertise required on the group and sought
external advice, we did not seek lay input. We cannot discount the
possibility that this would have changed our emphasis, around
patient reported outcome or experience measures for example.
Given the technical nature of our guidance we think it unlikely
this would have changed our conclusions. An inherent risk of the
consensus group design is ‘group think’ in which members trying
to reach consensus fail to critically evaluate alternative views. To
address this we sought critical evaluation by two highly eminent
international experts in this field. Although these were also, of
necessity, experts in antimicrobial stewardship research, the
impact of their input on our thinking, the breadth and seniority of
expertise in our group make it unlikely we have failed to consider
major alternative viewpoints. Notwithstanding these caveats, we
believe that application of this guidance has the potential to
greatly improve the quality and impact of antimicrobial stew-
ardship research.Summary recommendations
Outcomes
 Researchers should determine whether their study aims to
investigate, effectiveness or implementation (‘what or ‘how’).
This will determine the priority and nature of outcomes.
 All antimicrobial stewardship studies should define process,
clinical and microbiological outcomes and specify a primaryerent aspects of design is set out in the supplementary materials
Design aspect addressed
at’ and ‘how’ questions? Selection and prioritization of outcomes
How clusters will be defined within the study
What study design will be most appropriate.
Selection and timing of study outcomes
Cluster selection; feasibility of blinding; data collection
Cluster selection; feasibility of blinding; data collection
Feasibility of blinding
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intervention.
 Unless there is pre-existing evidence that a stewardship inter-
vention cannot or will not compromise treatment outcome, an
evaluation should attempt to prespecify a co-primary clinical/
microbiological efficacy outcome on which the study is
adequately powered or, at minimum, a single, lead clinical
outcome.
 Clinical and microbiological data documenting treatment
outcome should be collected and reported as prespecified sec-
ondary outcomes even if the study is not powered on them
 Measurement of incidence of infections/colonization due to
multidrug-resistant bacteria and infections due to C. difficile
infection should be included in the design of stewardship in-
terventions whenever possible. Studies assessing resistance
should clarify whether this is related to the infecting pathogen
or among colonizers.Objectives
 If a relevant clinical benefit can be hypothesized for an inter-
vention, then the research objective should seek superiority for
an appropriate primary clinical outcome.
 If not, researchers should seek both superiority for an appro-
priate process measure and ideally non-inferiority for a co-
primary clinical/clinically relevant microbiological outcome.
 Researchers should justify how the non-inferiority margin has
been selected and balanced against research costs and
feasibility.
 Where this is not possible, as a minimum, researchers should
specify, and report point estimates and confidence intervals for,
at minimum, a single prespecified lead clinical outcome.
 In situations where the study size is determined by a co-primary
non-inferiority safety outcome, an interim futility analysis of the
superiority process outcome should be considered to confirm a
relevant change in treatment/management.Study design
 Cluster randomized controlled trials (including crossover and
stepped-wedge designs) are preferable to quasi-experimental
before/after studies.
 The threshold for defining clusters should be as low as possible
to minimize contamination, allowing the maximum number of
clusters to be studied.
 In a parallel cluster RCT, randomization should not be relied on
to control for imbalance between study arms if the number of
clusters is <20 per arm and stratified or matched randomization
should be considered
 Designs using within-cluster comparisons (stepped-wedge
cRCT, crossover cRCT or quasi-experimental approaches) are
indicated where there are fewer than ten clusters per arm.
 Quasi-experimental studies should incorporate appropriate
controls and analyses to account for time trends.
 In quasi-experimental studies, timing of the intervention should
be externally set or if this is not possible timing should be
explained and described.
 Segmented regression analysis of interrupted time series studies
should include 12 time points with at least 100 observations per
time point before and after the intervention to allow for antic-
ipated secular trends and test or correct for autocorrelation.
 Single centre studies using a robustly designed and analysed
interrupted time series approach including observations beforeand after the intervention should be considered the lowest
quality research design which will impact on clinical practice.
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